Bench to bedside: the development of rapamycin and its application to stent restenosis.
Marx
S O
SO
Marks
A R
AR
D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects; D000818:Animals; D065095:Calcineurin Inhibitors; D002352:Carrier Proteins / Q000378:metabolism; D018797:Cell Cycle Proteins / Q000378:metabolism; D002455:Cell Division / Q000187:drug effects; D002465:Cell Movement / Q000187:drug effects; D002986:Clinical Trials as Topic; D000077144:Clopidogrel; D003324:Coronary Artery Disease / Q000601:surgery; D050760:Cyclin-Dependent Kinase Inhibitor p27; D015536:Down-Regulation / Q000187:drug effects; D006083:Graft Occlusion, Vascular / Q000175:diagnosis / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D006965:Hyperplasia / Q000175:diagnosis / Q000517:prevention & control*; D046911:Macromolecular Substances; D017853:Phosphotransferases (Alcohol Group Acceptor); D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D015398:Signal Transduction / Q000187:drug effects; D020123:Sirolimus / Q000378:metabolism / Q000627:therapeutic use*; D015607:Stents / Q000009:adverse effects; D058570:TOR Serine-Threonine Kinases; D016559:Tacrolimus / Q000494:pharmacology; D022061:Tacrolimus Binding Protein 1A / Q000378:metabolism; D013988:Ticlopidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D025521:Tumor Suppressor Proteins; D017540:Tunica Media / Q000187:drug effects / Q000473:pathology; D014654:Vascular Patency / Q000187:drug effects
D065095:Calcineurin Inhibitors; D002352:Carrier Proteins; D018797:Cell Cycle Proteins; D046911:Macromolecular Substances; D010975:Platelet Aggregation Inhibitors; D025521:Tumor Suppressor Proteins; D050760:Cyclin-Dependent Kinase Inhibitor p27; D000077144:Clopidogrel; D017853:Phosphotransferases (Alcohol Group Acceptor); C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases; D022061:Tacrolimus Binding Protein 1A; D013988:Ticlopidine; D020123:Sirolimus; D016559:Tacrolimus